Research leadership in the context of scientific and technological change
Cutting-edge research strategies need to motivate investigators, attract partners and investment, inspire the public and remain ahead of the scientific curve. To serve these objectives, a research strategy must project substance: rooted in thoughtful perspectives on the direction of scientific knowledge and technology; informed by an honest appraisal of a research organization’s differentiating and competitive strengths; and positioned to address the priorities of patients, health systems and society.
Shift Health works with research funders, universities, academic health centres, research institutes and the private sector to develop substantive research strategies that position our clients at the scientific frontiers. Combined with deep business acumen, our backgrounds in health research allow us to speak the language of researchers in order to build trust and confidence, decipher scientific trends important to an organization’s future, and identify opportunities to unleash discovery and help organizations lead the way.
Disease Area Strategy – Innovation Strategy – Commercialization Strategy
CIHR’s Institute of Infection & Immunity (III) engaged Shift Health to support the development of a 5-year strategic plan that reflected the research interests and strengths of Canada’s infection and immunity research community and the implications of the COVID-19 pandemic.
The Saudi Government aimed to create a national health research agency to strengthen the research and innovation ecosystem, support a learning healthcare system and diversify the Kingdom’s knowledge economy.
Cancer research stakeholders across Canada recognized the need for a unifying vision that would inspire collective action and prepare Canada for leadership in a rapidly evolving cancer research landscape.
Shift Health was engaged to support a top-5 global pharmaceutical company in defining its role and priorities in the evolving HIV disease management landscape.
Shift Health and University Health Network (UHN) were engaged by Halton Healthcare to assess the current state of research across a multisite hospital system and define the future direction of its clinical research program.
The International AIDS Society (IAS) required support to develop a 5-year strategy for the Global HIV Vaccine Enterprise (the Enterprise)—a long-time convenor and facilitator for the HIV vaccine R&D field.